Tonix Pharmaceuticals (NASDAQ:TNXP) posted its quarterly earnings data on Friday. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04, MarketWatch Earnings reports.
Shares of NASDAQ:TNXP opened at $0.58 on Friday. The firm has a market capitalization of $6.51 million, a P/E ratio of -0.20 and a beta of 1.48. Tonix Pharmaceuticals has a 12-month low of $0.52 and a 12-month high of $5.11.
A number of research firms have recently issued reports on TNXP. Roth Capital reiterated a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Tonix Pharmaceuticals in a research note on Friday, July 27th. Brookline Cap M lowered shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. Finally, B. Riley reiterated a “neutral” rating and set a $8.00 price objective on shares of Tonix Pharmaceuticals in a research note on Friday, July 27th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Tonix Pharmaceuticals currently has an average rating of “Buy” and an average target price of $4.50.
COPYRIGHT VIOLATION WARNING: “Tonix Pharmaceuticals (TNXP) Posts Earnings Results, Beats Expectations By $0.04 EPS” was first published by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/11/10/tonix-pharmaceuticals-tnxp-posts-earnings-results-beats-expectations-by-0-04-eps/2972875.html.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Further Reading: Market Capitalization in the Stock Market
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.